Atlas Trials

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Clinical trial NCT05110196 · COMPLETED

Trial details

NCT number
NCT05110196
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Non-Small Cell Lung Carcinoma
Start date
2022-09-03
Primary completion
2025-08-04
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.